Bristol Zerit XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb's once-daily nucleoside analogue Zerit XR (stavudine) clears FDA Dec. 31, giving each of the firm's HIV therapies a once-daily formulation. Bristol also submitted once-daily data for its pending protease inhibitor, atazanavi